BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liao M, Zhang J, Wang G, Wang L, Liu J, Ouyang L, Liu B. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. J Med Chem 2021;64:2382-418. [PMID: 33650861 DOI: 10.1021/acs.jmedchem.0c01180] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Tanaka T, Ohishi T, Saito M, Kawada M, Kaneko MK, Kato Y. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers. Monoclon Antib Immunodiagn Immunother 2022;41:32-8. [PMID: 35225665 DOI: 10.1089/mab.2021.0056] [Reference Citation Analysis]
2 Zhen Y, Yuan Z, Zhang J, Chen Y, Fu Y, Liu Y, Fu L, Zhang L, Zhou XL. Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer. Cell Death Dis 2022;13:375. [PMID: 35440104 DOI: 10.1038/s41419-022-04823-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Luo G, Lin X, Vega-Medina A, Xiao M, Li G, Wei H, Velázquez-Martínez CA, Xiang H. Targeting of the FOXM1 Oncoprotein by E3 Ligase-Assisted Degradation. J Med Chem 2021;64:17098-114. [PMID: 34812040 DOI: 10.1021/acs.jmedchem.1c01069] [Reference Citation Analysis]
4 Chakraborty A, Roy S, Chakraborty MP, Roy SS, Purkait K, Koley TS, Das R, Acharya M, Mukherjee A. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation. Inorg Chem 2021;60:18379-94. [PMID: 34780170 DOI: 10.1021/acs.inorgchem.1c02979] [Reference Citation Analysis]
5 Xu T, Zhang J, Yang C, Pluta R, Wang G, Ye T, Ouyang L. Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer. Eur J Med Chem 2021;219:113424. [PMID: 33862514 DOI: 10.1016/j.ejmech.2021.113424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wei D, Wang H, Zeng Q, Wang W, Hao B, Feng X, Wang P, Song N, Kan W, Huang G, Zhou X, Tan M, Zhou Y, Huang R, Li J, Chen XH. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem 2021;64:14822-47. [PMID: 34538051 DOI: 10.1021/acs.jmedchem.1c01350] [Reference Citation Analysis]
7 Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B, Liu B. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol 2022;15:44. [PMID: 35414025 DOI: 10.1186/s13045-022-01260-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Chen X, Shu C, Li W, Hou Q, Luo G, Yang K, Wu X. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem 2022. [PMID: 35447031 DOI: 10.1021/acs.jmedchem.2c00063] [Reference Citation Analysis]
9 Zhang J, Zou L, Shi D, Liu J, Zhang J, Zhao R, Wang G, Zhang L, Ouyang L, Liu B. Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer. J Med Chem 2021;64:14192-216. [PMID: 34605238 DOI: 10.1021/acs.jmedchem.0c02268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Xu J, Kim H, Dong J, Chen H, Xu J, Ma R, Zhou M, Wang T, Shen Q, Zhou J. Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents. Eur J Med Chem 2022;234:114229. [PMID: 35334447 DOI: 10.1016/j.ejmech.2022.114229] [Reference Citation Analysis]
11 Altei WF, Pachane BC, Souza C, Marques MMC, Selistre-de-Araújo H. New insights into the discovery of drugs for triple-negative breast cancer metastasis. Expert Opin Drug Discov 2022;:1-12. [PMID: 35179448 DOI: 10.1080/17460441.2022.2039619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Samadi M, Majidzadeh-A K, Salehi M, Jalili N, Noorinejad Z, Mosayebzadeh M, Muhammadnejad A, Sharif Khatibi A, Moradi-Kalbolandi S, Farahmand L. Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo. J Biol Eng 2021;15:20. [PMID: 34344421 DOI: 10.1186/s13036-021-00269-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy. J Med Chem 2022. [PMID: 35442700 DOI: 10.1021/acs.jmedchem.2c00135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen J, Ouyang L, Wu F, Zhang J, Chen L. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol 2022;15:89. [PMID: 35799213 DOI: 10.1186/s13045-022-01310-7] [Reference Citation Analysis]
15 He S, Zhao D, Ling Y, Cai H, Cai Y, Zhang J, Wang L. Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells. Front Pharmacol 2021;12:796534. [PMID: 34975493 DOI: 10.3389/fphar.2021.796534] [Reference Citation Analysis]